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Wedescribe afatalcaseofimported malariawherethesoleﬁndingrevealed atthepostmortemevaluationwasanacutelymphocytic
myocarditis with myocardiolysis. This case recalls the potential importance of myocardial injury in the prognosis of malaria and
prompts a reevaluation of current perspectives on the pathogenesis of severe falciparum infection. In the light of this, we have
reviewed the cases of cardiac complications in malaria published to date.
1.Introduction
Malaria still remains one of the major health problems
especially in developing countries. An estimated 250 million
cases led to nearly one million deaths in 2006, mostly of
children under 5 years [1]. If not recognized promptly,
P. falciparum malaria can in fact retain a high case-fatality
rate, especially in nonimmune persons. Cerebral malaria
remains the most common clinical presentation and cause
of death [2]. In contrast, myocardial failure and cardiac
arrhythmias have been rarely reported in course of severe
malaria despite the well known sequestration of parasitized
erythrocytes in the myocardial vessels and the potential
cardiac toxicity of antimalarial drugs. However, primary
myocardial involvement has recently been observed in a few
cases of imported severe falciparum malaria; all of these
cases exhibited a particularly severe clinical course, and two
deceases were recorded [3, 4]. We describe a fatal case of
malaria in which the primary cause of death revealed by the
post mortem evaluation was acute myocarditis.
2.CasePresentation
A 50-year-old Italian man was admitted to the hospital
because of severe febrile illness associated with profound
malaise, headache, sweating, and worsening jaundice of ﬁve-
day duration. Two weeks before the onset of sickness he
had returned from a business trip in Cameroon. The patient
had not taken any chemoprophylaxis against malaria. He
was obese (weight 98Kg; height 176cm), and an excessive
use of alcohol was reported. He had not previously suﬀered
from hypertension or any other known cardiovascular
disease. Upon admission, he complained additionally of
nausea, vomiting, and diarrhoea. He was fully conscious,
normotensive with a blood pressure of 120/80mm/Hg,
but clinical examination revealed tachycardia and severe
jaundice; his peripheral oxygen saturation was 95%. A
neurological inspection did not show signiﬁcant alterations.
Full blood count revealed thrombocytopenia (17 × 109/L),
haemoglobin at 14.6g/dL, and white cell count at 10 ×
109/L.Liverfunctiontestsdocumentedhyperbilirubinaemia,
moderate increase in serum transaminases, and moderate
renal impairment; blood glucose levels were also raised.
Coagulation screen did not show evidence of disseminated
intravascular coagulation. Cardiac enzymes were normal
(Table 1). A blood ﬁlm revealed a heavy P. falciparum
parasitaemia of 20%. A chest X-ray was normal, and the
unique alteration observed in the electrocardiogram (ECG)
was a low amplitude in QRS complexes. Serological testing
for Cytomegalovirus, Epstein-Barr virus, seasonal inﬂuenza2 Case Reports in Medicine
Table 1: Patient biochemical parameters detected during hospital stay.
Normal range Day 1 Day 2 Day 3
(5:30PM) (7:00AM) (6:00AM)
WBC (×109/L) 3.5–11.0 9.0 17.7 23.8
RBC (×1012/L) 4.1–5.65 3.84 2.93 2.90
Haemoglobin (g/dL) 12.5–16.9 12.6 9.3 9.0
PLT (×109/L) 110–330 17 37 59
Creatinine (mg/dL) <1.3 2,58 3.72 5,24
GFR (mm/h) >90 26 17 11
Glycaemia (mg/dL) 60–126 167 144 157
Sodium (mmol/L) 135–145 136 137 143
Calcium (mg/dL) 8.5–10.5 8.1 7.7 7.8
Potassium (mmol/L) 3.3–5.0 4 4.3 4
Chloride (mmol/L) 95–110 100 102 104
Lactic dehydrogenase (lUlL) 200–420 1951 — 2479
AST (lUlL) <37 129 110 108
ALT (lUlL) <53 115 71 76
Total bilirubin (mg/dL) 0.3–1.5 11.5 23.5 23.5
Direct bilirubin (mg/dL) 0.1–0.6 6.5 14.8 14.8
Creatine phosphokinase (lUlL) <200 89 74 —
Troponin (ng/mL) <0.07 0.0 — —
Myoglobin (ng/mL) <110 91 — —
PT (seconds) 11.0–13.5 11 — 12
PTT (seconds) 25–38 36 — 33
INR 0.7–1.2 1.1 — 1.2
Fibrinogen (mg/dL) 200–400 384 — 577
viruses A and B, adenoviruses, Chlamydia psittaci, Cox-
iella burnetii, Mycoplasma pneumoniae,r e s p i r a t o r ys y n c y t i a l
virus, the Widal-Wright reaction and the slide macro-
agglutinationtest forleptospirosis were negative. The patient
was treated with 10mg/kg b.w. (namely, 1000mg) of
I.V. quinidine gluconate t.i.d., plus ceftriaxone 2g q24h
I.V. and oral doxycycline 100mg b.i.d., while waiting
for the results of blood cultures. Within 12 hours of
admission, a slow but progressive worsening of multior-
gan failure was observed despite a marked reduction of
parasitaemia. Given the severity of clinical setting, I.M.
artemisin (300mg loading dose, followed by 100mg/daily)
was initiated. At 40 hours after admission, the patient
worsened suddenly. He became restless, confused, bradi-
arythmical, hypotensive (80/60 mmHg), and died in spite
of prompt mechanical ventilation and cardiac resuscitation.
The post-mortem evaluation revealed acute heart failure
(bilateral pulmonary oedema) but no signs of myocardial
ischaemia. The liver and the spleen were not enlarged.
However, an histology of severe acute myocarditis with
myocardiolysis was detected: diﬀuse lymphocytic inﬁltrates
were surrounding the myocardial capillaries, inside which
some intravascular parasitized RBCs were visible (Figure 1).
No sequestered parasites could be revealed in brain ves-
sels.
3.Discussion
According to the WHO criteria, severe P. falciparum malaria
in adultsisdeﬁnedbyoneormore ofthefollowing: impaired
consciousness with unarousable coma, jaundice, progressive
renal impairment, metabolic acidosis, hyperlactataemia and
hypoglycaemia, respiratory distress, pulmonary oedema and
severe anaemia. The pathogenetic mechanism is believed
to consist mainly of impaired tissue perfusion resulting in
hypoxaemiaandmetabolicacidosis.Primarycardiacinvolve-
mentisthoughttoberareandmyocardialfunctionpreserved
even in severe disease [2, 5–7]. Haemodynamic changes have
been found to be compatible with systemic and pulmonary
vasodilation,andincreasedpulmonaryvascularpermeability
tobethecauseofpulmonary oedema[8].Nevertheless,there
are some reports of myocardial involvement [3, 4, 9–13]
(Table 2), sometimes associated with a fatal outcome.
A raised cardiac index has repeatedly been observed in
patients with severe malaria, and proposed to depend on
the cytokine-mediated low vascular resistance triggered by
parasite-derived pyrogens [8, 14]. There was also evidence,
in complicated P. falciparum malaria cases compared to
uncomplicatedcases[15],ofasigniﬁcant increase inthelevel
of N-terminal probrain natriuretic peptide (NT proBNP,
a sensitive marker of impaired left ventricular function),Case Reports in Medicine 3
(a) (b)
Figure 1: Acute myocarditis due to P. falciparum. (a) Extensive lymphocytic inﬁltrates surrounding myocardial capillaries and (b)
Lymphocytes and parasitized RBCs sequestered in the lumen. Haematoxylin and eosin, ×20 (a) and ×40 (b); original magniﬁcation.
Table 2: Cases of cardiac complications in severe malaria (reported as of January 2011).
Reference No. of
cases Organism Concomitantmorbidity Clinical setting Outcome
Herrera [9]1 P. vivax None ischaemic myocarditis Death
Mohsen et al. [3]1 P. falciparum None acute myocarditis Cure
Wichmann et al. [4]2P. falciparum Unknown myocarditis (1 pt)
unknown (1 pt)
Death
Death
Tripathy et al. [10]1 P. falciparum N/A myocarditis N/A
Wennicke et al. [11]1P. falciparum Unknown acute heart failure Death
Kim et al. [12]1 P. vivax None myocarditis Cure
Kumar et al. [13]2 P. falciparum None acute heart failure (1 pt)
ventricular ﬁbrillation (1pt)
Cure
Death
Present case 1 P. falciparum Obesity, increased alcohol intake myocarditis Death
heart-type fatty acid-binding protein (H-FABP, a marker
of acute myocardial injury), myoglobin and creatine kinase
muscle-brain (CK-MB) (both established markers of myo-
cardial injury and necrosis) even in patients who did not
display signiﬁcant ECG abnormalities. In another study, the
serum concentration of cardiac troponin T was found to be
elevated only in in a very low (0.6%) proportion of patients
[7], although ECG aspeciﬁc abnormalities—such as, delayed
conduction and/or T or ST alterations—were observed in
14.3% of patients, suggesting that the electrophysiology of
cardial myocites can be altered before myocytolysis occurs.
Autopsy data supports the view that the mechanical
blockage of capillaries exerted by malarial parasites and
parasitized red blood cells (PRBCs) can lead to ischaemic
cardiomyopathy [4, 9, 11, 16]; the severity of clinical features
was thus put in relation with the high burden of PRBCs,
which exhibited an increased ability to sequester in the deep
microvasculature [17]. However, in two fatal cases of P. falci-
parum infection the only signiﬁcant ﬁnding detected at post-
mortem evaluation was an acute lymphocytic myocarditis
[4]. More recently, myocarditis was also observed as a com-
plication of P. vivax infection [12]. Therefore, a reevaluation
ofcurrentperspectivesonthepathophysiologyofmyocardial
dysfunction in course of severe malaria appears to be neces-
sary. Toxiceﬀectsduetocytokinessuchasthetumornecrosis
factor (TNF), have been claimed to play an important
role [18–20]. An overexpression of caspases and calpains—
which are believed to be inducers of apoptosis—in the
presence of PRBCs and TNF described in a report [21],
was not conﬁrmed subsequently [22]. Instead, plasmodial
glycosylphosphatidylinositol (GPI)—either free or linked to
surface antigens—was proven,in a murine model, to retain a
direct eﬀect (i.e., independent from cytokine production by
monocytes) on cardiac myocytes [23]. More recently, such
an eﬀect was determined as an upregulation of apoptotic
genes and of a myocardial damage marker (NT proBNP),
suggesting that GPI might induce myocyte apoptosis and
therefore be one cause of malaria myocarditis [11]. In
summary, at the present state of knowledge myocardial
damageappearstoretainamultifactorialpathogenesis,being
probablythe result ofmechanical (microcirculatory obstruc-
tion), metabolic (systemic acidosis and related tissue hypo-
oxigenation), and humoral mechanisms. However, cardiac
side eﬀects related to therapy should also be considered.
Quinine may evoke arrythmias, angina, and hypotension,
potentially causing circulatory failure and/or cardiac arrest
[14]. However, these eﬀects are rare and generally occur
when the drug is injected rapidly: noticeably, cardiovascular
collapse is generally an eﬀect of acute toxicity manifesting
when infusion is initiated [2, 24]. None of these side eﬀects4 Case Reports in Medicine
could be ascertained in our case, nor could the autopsy
reveal any organ abnormality potentially in relation with
the cardiotoxicity of quinine, which had been administered
in a currently accepted dosage (i.e., loading dose of 15–
20mg/kg followed by 10mg/kg t.i.d.). The experience on
quinine dosing in obesity is limited, and dose adjustment
for renal impairment is not recommended within the ﬁrst
48 hours of treatment, since its metabolism is thought
to be mainly hepatic [25]. To date, there is no direct
evidence for signiﬁcant cardiovascular eﬀects of artesunate
[25, 26], although a case of limited myocardial necrosis
occurring just after completion of antimalarial treatment
with artemether/lumefantrine was recently reported in an
experimentally infected healthy volunteer, raising an issue of
diﬀerential diagnosis between acute coronary syndrome and
myocarditis [27].
In our case, additional risk factors for cardiomyopathy,
such as obesity and increased alcohol intake, might have
contributed to the severity of the disease. However, in spite
of the severity of his clinical presentation, our patient did
not develop any impairment of consciousness or other
neurological symptoms. Instead, he had a clinical picture
of multiple-organ failure with metabolic acidosis, and in
a few hours deteriorated despite supportive and speciﬁc
antimalarial treatment. The myocarditis, revealed by post-
mortem histology, was unexpected. The pathological ﬁnding
of active lymphocytic myocarditis usually correlates with
either acute myocardial infarction-like syndrome (with nor-
mal coronary arteries) or heart failure, with normal-sized or
dilated left ventricle and haemodynamic compromise [28].
Interestingly, in our patient the second scenario appears to
be the most likely, even though it was so far documented in
cases who had exhibited much longer courses of disease.
O u re x p e r i e n c es u g g e s t st h a ti nc o u r s eo fs e v e r eP. fal-
ciparum malaria the frequency of primary cardiac compli-
cations may be underestimated, especially in adult patients
with cardiovascular risk factors (i.e., obesity, smoking,
diabetes, hypertension, advanced age), but also in case of
unknown or silent underlying cardiomyopathy.
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